Cargando…

Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?

Pharmacokinetic/pharmacodynamic data from real-world cohort are sparse in non small–cell lung cancer (NSCLC) patients treated with nivolumab. The aim of this prospective observational study was to explore the exposure-response relationship for effectiveness and toxicity of nivolumab in 81 outpatient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bellesoeur, Audrey, Ollier, Edouard, Allard, Marie, Hirsch, Laure, Boudou-Rouquette, Pascaline, Arrondeau, Jennifer, Thomas-Schoemann, Audrey, Tiako, Manuela, Khoudour, Nihel, Chapron, Jeanne, Giraud, Frédérique, Wislez, Marie, Damotte, Diane, Lupo, Audrey, Vidal, Michel, Alexandre, Jérôme, Goldwasser, François, Tod, Michel, Blanchet, Benoit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895963/ https://www.ncbi.nlm.nih.gov/pubmed/31766292 http://dx.doi.org/10.3390/cancers11111784

Ejemplares similares

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
por: Tiako Meyo, Manuela, et al.
Publicado: (2020)

Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
por: Noé, Gaëlle, et al.
Publicado: (2019)

Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients
por: Minot-This, Marie-Sophie, et al.
Publicado: (2022)

Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study
por: Boudou-Rouquette, Pascaline, et al.
Publicado: (2021)

Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study
por: Boudou-Rouquette, Pascaline, et al.
Publicado: (2012)

Pericardial effusion under nivolumab: case-reports and review of the literature
por: Anastasia, Saade, et al.
Publicado: (2019)

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort
por: Damotte, Diane, et al.
Publicado: (2019)

Correction to: Pericardial effusion under nivolumab: case-reports and review of the literature
por: Saade, Anastasia, et al.
Publicado: (2019)

Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer
por: Rodier, Thomas, et al.
Publicado: (2022)

Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab
por: Noel, Johanna, et al.
Publicado: (2022)

Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib
por: Noé, Gaёlle, et al.
Publicado: (2016)

Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with Elisa
por: Millet, Aurélien, et al.
Publicado: (2021)

Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma
por: Mir, Olivier, et al.
Publicado: (2012)

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
por: Bellesoeur, Audrey, et al.
Publicado: (2017)

Lung Involvement in Chronic Schistosomiasis with Bladder Squamous Cell Carcinoma
por: Saade, Anastasia, et al.
Publicado: (2018)

Pre-Disease and Pre-Surgery BMI, Weight Loss and Sarcopenia Impact Survival of Resected Lung Cancer Independently of Tumor Stage
por: Icard, Philippe, et al.
Publicado: (2020)

Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study
por: Jouinot, Anne, et al.
Publicado: (2018)

Unexpected pulmonary tumour in a young woman
por: Boulle, Geoffroy, et al.
Publicado: (2019)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
por: Balakirouchenane, David, et al.
Publicado: (2020)

Updated Prognostic Factors in Localized NSCLC
por: Garinet, Simon, et al.
Publicado: (2022)

First referral to an integrated onco-palliative care program: a retrospective analysis of its timing
por: Barth, Claire, et al.
Publicado: (2020)

Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options
por: Tlemsani, Camille, et al.
Publicado: (2023)

Development, Validation, and Comparison of Two Mass Spectrometry Methods (LC-MS/HRMS and LC-MS/MS) for the Quantification of Rituximab in Human Plasma
por: Millet, Aurélien, et al.
Publicado: (2021)

Adverse events of targeted therapies approved for women's cancers
por: Saint-Ghislain, Mathilde, et al.
Publicado: (2021)

A new strategy to target regulatory T cells in solid tumors
por: Thomas-Schoemann, Audrey, et al.
Publicado: (2013)

Dimethyl fumarate is highly cytotoxic in KRAS mutated cancer cells but spares non-tumorigenic cells
por: Bennett Saidu, Nathaniel Edward, et al.
Publicado: (2018)

Twenty-Year Survival of Patients Operated on for Non-Small-Cell Lung Cancer: The Impact of Tumor Stage and Patient-Related Parameters
por: Schussler, Olivier, et al.
Publicado: (2022)

Pituitary Lesion of Unknown Origin: Think Epithelioid Angiosarcoma
por: Bricaire, Léopoldine, et al.
Publicado: (2017)

Real-Time Imaging of Resident T Cells in Human Lung and Ovarian Carcinomas Reveals How Different Tumor Microenvironments Control T Lymphocyte Migration
por: Bougherara, Houcine, et al.
Publicado: (2015)

Ex Vivo Imaging of Resident CD8 T Lymphocytes in Human Lung Tumor Slices Using Confocal Microscopy
por: Peranzoni, Elisa, et al.
Publicado: (2017)

Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study
por: Velev, Maud, et al.
Publicado: (2021)

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer
por: Mogenet, Alice, et al.
Publicado: (2023)

Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study
por: Marin, Clémence, et al.
Publicado: (2021)

Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?
por: Mansuet-Lupo, Audrey, et al.
Publicado: (2014)

Influence of stromal elements on resident T cell migration in human and murine tumors analyzed by real-time imaging
por: Peranzoni, Elisa, et al.
Publicado: (2015)

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
por: Huillard, O, et al.
Publicado: (2013)

Primary Cutaneous Mucinous Carcinoma Monitoring: A Role for CA15.3 and CEA?
por: Ginguay, Antonin, et al.
Publicado: (2022)

Dispersal syndromes and the use of life-histories to predict dispersal
por: Stevens, Virginie M, et al.
Publicado: (2013)

Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes
por: Wells, Leah, et al.
Publicado: (2022)

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
por: Tiako Meyo, Manuela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_agidel0j83srlkukjn65q7mb46